News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proxima Therapeutics Partners With Nucletron B.V. To Introduce MammoSite Therapy For Breast Cancer In Australia And New Zealand


10/19/2005 5:12:21 PM

Proxima Therapeutics today announced that Nucletron will be the exclusive distributor of the MammoSite Radiation Therapy System in Australia and New Zealand. MammoSite was developed by Proxima and cleared by the United States Food and Drug Administration (FDA) in May 2002 and received Australian Registration in June 2003. With this partnership, a five-day treatment regimen of partial breast irradiation with MammoSite will now be available to more than 11,000 women diagnosed with breast cancer each year in Australia and New Zealand.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES